<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660346</url>
  </required_header>
  <id_info>
    <org_study_id>IL-10 MRSaB</org_study_id>
    <nct_id>NCT02660346</nct_id>
  </id_info>
  <brief_title>IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB</brief_title>
  <official_title>A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharp HealthCare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies
      have shown that an elevated IL-10 level is an independent risk factor of mortality. It may
      also serve as biomarker for very early risk stratification. The aim of this study is to
      compare the outcomes for patients with elevated IL-10 levels (≥8 pg/ml) when treated with
      standard antibiotic therapy (daptomycin or vancomycin) versus early aggressive therapy
      (daptomycin with ceftaroline) for the treatment of MRSaB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with MRSaB have primary therapeutic failure rates of 40-50% and high mortality rate
      of 10-50% when treated with the recommended standard antimicrobial therapy. (Sharp) local
      data for MRSaB for 2014 shows an all-cause mortality rate of 29%. Recent studies have been
      published that utilize the predictive biomarker, IL-10, aiding the understanding for the wide
      variability in mortality. Further studies are needed to elucidate the clinical relevance of
      utilizing IL-10 levels to optimize MRSaB management and whether or not patient outcomes are
      enhanced.

      Under current standard treatment strategies, vancomycin 15 mg/kg IVPB every 12 hrs following
      a 30 mg/kg IVPB loading dose is the first line of antibiotic therapy initiated with known or
      suspected MRSaB. Only when patients have showed an unsatisfactory clinical response such as
      prolonged bacteremia and/or continued clinical signs of uncontrolled infection are more
      potent/aggressive and more expensive antibiotic choices considered in most cases. Even the
      time for consideration of such a switch is a matter of controversy, with current MRSA
      treatment guidelines recommending a switch after 7-days of failure.

      Several recent studies have shown that an elevated IL-10 level is an independent risk factor
      of mortality. In animal models, it has been shown that the bacterial cell wall of
      Staphylococcus aureus stimulates the production of IL-10. A small study by Rose et al. showed
      that this observation is consistent in humans. In another study, the authors concluded that
      elevated IL-10 at the time of presentation is a predictive value of mortality in patients
      with MRSaB4. In addition, the authors concluded that IL-10 may serve as a biomarker for very
      early risk stratification, with selection of standard therapy for low-risk patients and more
      potent, expensive, and cumbersome antibiotic therapies reserved for the high-risk patients.
      Furthermore, it is postulated that treating high risk patients with aggressive/intensified
      therapy earlier may improve economic and microbiological outcomes, such as a decreased length
      of treatment, decreased time in the Intensive Care Unit, decreased length of stay in the
      hospital, and decreased duration of bacteremia.

      The aim in this study is to compare the outcomes for patients with elevated IL-10 levels (≥ 8
      pg/mL) when treated with standard antibiotic therapy versus early aggressive therapy for the
      treatment of MRSaB. Aggressive therapy is defined in study to be daptomycin (6-8mg/kg/day)
      with ceftaroline (600 mg q8hr).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to bacteremia clearance</measure>
    <time_frame>1-4 weeks</time_frame>
    <description>To determine whether or not early aggressive antibiotic therapy are correlated to shorter time to bacteremia clearance compared to standard therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of IL-10 levels between standard and aggressive therapy treatments</measure>
    <time_frame>About 2 months from blood draw to the batch results</time_frame>
    <description>To determine whether or not patients who have high IL-10 levels treated with aggressive antibiotic therapy have better outcomes compared with standard therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Group A - Daptomycin or Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Therapy of physician's choice, usually daptomycin 6-8 mg/kg IVPB daily or vancomycin IVPB adjusted dose per site protocol with a goal vancomycin trough level: 15-20 mcg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Daptomycin with Ceftaroline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daptomycin (6-8 mg/kg/day IVPB daily) with Ceftaroline (600 mg IVPB q8hr) to start within 72hrs of hospital admission. Daptomycin will be renally adjusted per package insert. Ceftaroline will be renally adjusted per institutional renal dosing recommendations for Q8h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.</description>
    <arm_group_label>Group A - Daptomycin or Vancomycin</arm_group_label>
    <arm_group_label>Group B - Daptomycin with Ceftaroline</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Control Arm Treatment</description>
    <arm_group_label>Group A - Daptomycin or Vancomycin</arm_group_label>
    <other_name>Vancocin HCL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftaroline</intervention_name>
    <description>Study Arm Treatment</description>
    <arm_group_label>Group B - Daptomycin with Ceftaroline</arm_group_label>
    <other_name>Teflaro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (≥ 18 years of age) men or women.

          -  Diagnosis of MRSaB

          -  Has not been treated with antibiotics for MRSaB within 7 days of admission

          -  Has been on standard antibiotics for &lt; 72hrs prior to randomization

          -  In the opinion of the investigator, the subject must require and be a suitable
             candidate for IV antibiotic therapy.

        Exclusion Criteria:

          -  Medical history of hypersensitivity or allergic reaction to vancomycin, or vancomycin
             derivatives, daptomycin or ceftaroline

          -  Severe allergy to cephalosporins, i.e. Type 1 reaction, especially IgE mediated
             anaphylaxis

          -  Comfort care patients

          -  Death within 72hrs of the start of antibiotic therapy

          -  Polymicrobial bacteremia: Staphylococcus aureus and another gram positive, gram
             negative or anaerobic pathogen

          -  Burns covering ≥ 10% of body.

          -  Pt currently enrolled in an investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DeAnn Cary, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharp Grossmont Hospital</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.insidehopkinsmedicine.org/AMP</url>
  </link>
  <link>
    <url>https://shands-pharmacy-idresident.sites.medinfo.ufl.edu/files/2013/05/UHC-2012-ceftaroline-poster_present.pdf</url>
  </link>
  <reference>
    <citation>Wang FD, Chen YY, Chen TL, Liu CY. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia. Am J Infect Control. 2008 Mar;36(2):118-22. doi: 10.1016/j.ajic.2007.02.005.</citation>
    <PMID>18313513</PMID>
  </reference>
  <reference>
    <citation>van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012 Apr;25(2):362-86. doi: 10.1128/CMR.05022-11. Review.</citation>
    <PMID>22491776</PMID>
  </reference>
  <reference>
    <citation>Rose W, Berti AD, Hayney MS, Henriquez K, Ranzoni A, Cooper MA, Shukla SK, Proctor RA, Nizet V, Sakoulas G. Associaction of IL-10 concentrations with bacterial bloodstream inoculum and mortality in patients with Staphylococcus aureus bacteremia. 2014. Abstr. International Symposium Staphylococci &amp; Staphylococcal Infections. abstr 207.</citation>
  </reference>
  <reference>
    <citation>Rose WE, Eickhoff JC, Shukla SK, Pantrangi M, Rooijakkers S, Cosgrove SE, Nizet V, Sakoulas G. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis. 2012 Nov 15;206(10):1604-11. doi: 10.1093/infdis/jis552. Epub 2012 Sep 10.</citation>
    <PMID>22966128</PMID>
  </reference>
  <reference>
    <citation>Rooijakkers SH, Ruyken M, van Roon J, van Kessel KP, van Strijp JA, van Wamel WJ. Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell Microbiol. 2006 Aug;8(8):1282-93.</citation>
    <PMID>16882032</PMID>
  </reference>
  <reference>
    <citation>Frodermann V, Chau TA, Sayedyahossein S, Toth JM, Heinrichs DE, Madrenas J. A modulatory interleukin-10 response to staphylococcal peptidoglycan prevents Th1/Th17 adaptive immunity to Staphylococcus aureus. J Infect Dis. 2011 Jul 15;204(2):253-62. doi: 10.1093/infdis/jir276.</citation>
    <PMID>21673036</PMID>
  </reference>
  <reference>
    <citation>Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011 Aug 1;204(3):340-7. doi: 10.1093/infdis/jir270.</citation>
    <PMID>21742831</PMID>
  </reference>
  <reference>
    <citation>Spika JS, Peterson PK, Wilkinson BJ, Hammerschmidt DE, Verbrugh HA, Verhoef J, Quie PG. Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia. J Infect Dis. 1982 Aug;146(2):227-34.</citation>
    <PMID>7108273</PMID>
  </reference>
  <reference>
    <citation>Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014 Oct 1;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. Epub 2014 Jul 10.</citation>
    <PMID>25017183</PMID>
  </reference>
  <reference>
    <citation>Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011 Jul 15;53(2):158-63. doi: 10.1093/cid/cir340.</citation>
    <PMID>21690622</PMID>
  </reference>
  <reference>
    <citation>Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother. 2013 Mar;57(3):1192-200. doi: 10.1128/AAC.02192-12. Epub 2012 Dec 17.</citation>
    <PMID>23254428</PMID>
  </reference>
  <reference>
    <citation>Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013 Jan;57(1):66-73. doi: 10.1128/AAC.01586-12. Epub 2012 Oct 15. Erratum in: Antimicrob Agents Chemother. 2013 Mar;57(3):1565.</citation>
    <PMID>23070161</PMID>
  </reference>
  <reference>
    <citation>Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother. 2015 Feb;70(2):505-9. doi: 10.1093/jac/dku378. Epub 2014 Sep 22.</citation>
    <PMID>25246437</PMID>
  </reference>
  <reference>
    <citation>Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis. Open Forum Infect Dis. 2014 Jul 8;1(2):ofu046. doi: 10.1093/ofid/ofu046. eCollection 2014 Sep. Erratum in: Open Forum Infect Dis. 2015 Apr;2(2):ofv058.</citation>
    <PMID>25734118</PMID>
  </reference>
  <reference>
    <citation>Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother. 2013 Aug;57(8):4042-5. doi: 10.1128/AAC.02481-12. Epub 2013 May 20.</citation>
    <PMID>23689728</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>Matthew Geriak</investigator_full_name>
    <investigator_title>Investigational Research Pharmacist</investigator_title>
  </responsible_party>
  <keyword>IL-10</keyword>
  <keyword>MRSA</keyword>
  <keyword>Bacteremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan on sharing any IPD with other researchers until the study is complete.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

